FDA Fast-Tracks Custom Cancer Shot

A personalized cancer vaccine built from a patient’s own tumor has now cleared a major U.S. Food and Drug Administration (FDA) milestone and posted real survival gains in patients with deadly melanoma.

Story Snapshot

The FDA gave Breakthrough Therapy Designation to Moderna and Merck’s mRNA-4157/V940 cancer vaccine paired with Keytruda for high-risk melanoma patients after surgery
A Phase 2b trial called KEYNOTE-942 showed the combo cut the risk of cancer returning or death by 44 percent compared to Keytruda alone
Five-year follow-up data show the recurrence-free survival benefit held steady, and a larger Phase 3 trial is now confirming those results
Separate research finds COVID-19 mRNA vaccines may boost how well immunotherapy works in lung cancer and melanoma patients
Experts say the science marks real progress but caution that most cancer vaccines remain in testing, not routine care

The FDA Fast-Tracks a Personalized Vaccine

Moderna and Merck announced on February 22, 2023, that the FDA had granted Breakthrough Therapy Designation to their combination treatment. The vaccine, called mRNA-4157/V940, targets patients with high-risk melanoma who already had surgery to remove their tumors. It works alongside Keytruda, Merck’s approved immunotherapy drug pembrolizumab. This designation speeds up FDA review for treatments that show real promise against serious diseases.

The vaccine is built individually for each patient. Doctors sequence a patient’s tumor to find its unique genetic mutations, called neoantigens. Scientists then design an mRNA shot that trains the patient’s immune system to recognize and attack those specific markers. Europe’s medicine regulator followed the FDA’s lead two months later, granting its own accelerated review status in April 2023.

Trial Numbers Behind the Excitement

The excitement traces back to the Phase 2b KEYNOTE-942 trial. Patients who got the vaccine plus Keytruda saw a 44 percent drop in the risk of their melanoma returning or causing death, compared to patients who got Keytruda by itself. Researchers measured a hazard ratio of 0.56, a statistically strong result that first appeared in early findings and has held up in later reporting.

Five years out, that benefit has not faded. Moderna and Merck reported sustained improvement in recurrence-free survival at the five-year mark, meaning patients who got the personalized vaccine were still doing better than those on Keytruda alone. The companies have since moved into Phase 3 testing, the last major hurdle before a treatment can seek full approval, and reported in 2025 that the vaccine combination continued to lengthen the time before high-risk skin cancer patients relapsed.

A Second, Unexpected Discovery

Separate teams of researchers stumbled onto another surprising finding. Lung cancer and melanoma patients who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy lived noticeably longer than patients who skipped the shot. One study published in Nature reported that vaccinated lung cancer patients lived nearly twice as long as those who were not vaccinated.

Researchers controlled for dozens of other factors, including cancer stage, prior treatments, and overall health, and the survival link held up. Scientists think the COVID vaccine may temporarily wake up the immune system in a way that makes tumors more visible and vulnerable to checkpoint inhibitor drugs, converting so-called “cold” tumors into ones the immune system can actually fight.

Why Experts Urge Steady Optimism

Cancer vaccines have a long, humbling history. For decades, promising lab results failed to hold up once tested broadly in patients, largely because tumors are skilled at hiding from the immune system and suppressing its response. Current scientific reviews describe the field as entering an era of “renewed promise,” built on better antigen targeting, early treatment timing, and pairing vaccines with existing drugs rather than replacing them.

Even researchers most excited about these results are careful with their language. Reviews note that only one cancer vaccine has full market approval today, while most others, including mRNA-4157/V940, remain under clinical study rather than everyday use. That is not a knock against the science. It is simply a reminder that turning strong trial data into a treatment every oncologist can prescribe still takes time, more patients, and more proof.